COST-EFFECTIVENESS ANALYSIS OF ABIRATERONE ACETATE TREATMENT COMPARED WITH CABACITAXEL IN DOMINICAN REPUBLIC, IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER THAT HAVE FAILED TO CHEMOTHERAPY WITH DOCETAXEL

被引：0
|
作者：
Obando, C. A. [1 ]
Desanvicente-Celis, Z. [1 ]
Gonzalez, L. [2 ]
Muschett, D. [1 ]
Gonzalez, F. [1 ]
Goldberg, P. [1 ]
机构：
[1] Janssen, Panama City, Panama
[2] Janssen, Raritan, NJ USA
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 07期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN121
引用
收藏
页码：A635 / A635
页数：1
相关论文
共 50 条
  • [31] Cost-effectiveness analysis of enzalutamide for patients with chemotherapy-naive metastatic castration-resistant prostate cancer in Japan
    Okumura, Hiroyuki
    Inoue, Sachie
    Naidoo, Shevani
    Holmstrom, Stefan
    Akaza, Hideyuki
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2021, 51 (08) : 1319 - 1329
  • [32] New drugs in the treatment of metastatic castration-resistant prostate cancer: abiraterone acetate
    Martinez-Hernandez, Lucia
    Martinez-Prieto, Marcela
    Galvan-Salazar, Gabriel
    GACETA MEXICANA DE ONCOLOGIA, 2013, 12 (01): : 32 - 40
  • [33] COST-EFFECTIVENESS ANALYSIS OF ENZALUTAMIDE FOR PATIENTS WITH CHEMOTHERAPY-NAIVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER IN JAPAN
    Okumura, H.
    Inoue, S.
    Naidoo, S.
    Holmstrom, S.
    Akaza, H.
    VALUE IN HEALTH, 2017, 20 (05) : A107 - A107
  • [34] Abiraterone in the treatment of metastatic castration-resistant prostate cancer
    Mostaghel, Elahe A.
    CANCER MANAGEMENT AND RESEARCH, 2014, 6 : 39 - 51
  • [35] Sequencing of cabazitaxel and abiraterone acetate following docetaxel in metastatic castration-resistant prostate cancer (mCRPC)
    Schnadig, Ian D.
    Bhor, Menaka
    Vogelzang, Nicholas J.
    Hennessy, Daniel
    Nicacio, Leonardo V.
    Berry, William R.
    Hutson, Thomas E.
    Fleming, Mark T.
    Cowey, C. Lance
    Saravanan, Shanmugapriya
    Dhanda, Rahul
    Sonpavde, Guru
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [36] Response to Subsequent Docetaxel in a Patient Cohort With Metastatic Castration-Resistant Prostate Cancer After Abiraterone Acetate Treatment
    Aggarwal, Rahul
    Harris, Anna
    Formaker, Carl
    Small, Eric J.
    Molina, Arturo
    Griffin, Thomas W.
    Ryan, Charles J.
    CLINICAL GENITOURINARY CANCER, 2014, 12 (05) : E167 - E172
  • [37] Activity of cabazitaxel following docetaxel and abiraterone acetate in patients with castration-resistant prostate cancer
    Sella, Avishay
    Sella, Tal
    Peer, Avivit
    Berger, Raanan
    Frank, Stephen Jay
    Gez, Eli
    Sharid, David
    Hayat, Henry
    Hanovich, Ekaterina
    Kovel, Svetlana
    Rosenbaum, Eli
    Neiman, Victoria
    Keizman, Daniel
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [38] Feasibility of abiraterone acetate treatment in patients with metastatic castration-resistant prostate cancer and atrial fibrillation
    Rauch, Simon
    Fong, Dominic
    Morra, Elisa
    Maines, Francesca
    Caffo, Orazio
    Spizzo, Gilbert
    PROSTATE INTERNATIONAL, 2016, 4 (02) : 54 - 55
  • [39] A prognostic score for patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate post chemotherapy
    Templeton, Arnoud J.
    Omlin, Aurelius Gabriel
    Pezaro, Carmel Jo
    Kheoh, Thian San
    Leibowitz-Amit, Raya
    Vera-Badillo, Francisco Emilio
    Tannock, Ian
    Attard, Gerhardt
    Amir, Eitan
    De Bono, Johann Sebastian
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [40] Treatment with abiraterone in metastatic castration-resistant prostate cancer patients progressing after docetaxel: a retrospective study
    Cicero, Giuseppe
    De Luca, Rossella
    Blasi, Livio
    Pepe, Alessio
    Pavone, Carlo
    Simonato, Alchiede
    Dieli, Francesco
    ANTI-CANCER DRUGS, 2017, 28 (09) : 1047 - 1052
12345